Arrowsmith closes ¥1.05bn Series A for phage-therapy push toward FDA trials
What's the deal? Arrowsmith, a Tsukuba-based drug discovery startup, has closed a ¥1.05 billion Series A round.
The company develops phage therapy, which uses bacteriophages — viruses that prey on bacteria — to treat infections that antibiotics can no longer beat.
Investors include JAFCO GroupDealroom has a profile for this one. Try Dealroom →, JIC Venture Growth InvestmentsDealroom has a profile for this one. Try Dealroom →, ANRIDealroom has a profile for this one. Try Dealroom →, and DBJ CapitalDealroom has a profile for this one. Try Dealroom →. The first three joined in the first close; DBJ Capital came in second.
Why now? The raise lands alongside a regulatory milestone. Arrowsmith held a Pre-IND meeting with the US Food and Drug Administration and received written feedback in late December 2025 on ARW001, its lead phage cocktail targeting Pseudomonas aeruginosa infections.
The agency raised no major objections to the trial design, the data package, or the plan to skip GLP toxicity studies. Arrowsmith now aims to file its IND and start its first clinical trial within 2026.
What could go wrong? Phage therapy remains largely unproven in modern Western clinical practice. Early-stage drug development carries high failure rates, and a positive Pre-IND signal does not guarantee trial success or eventual approval.
ARW001 relies on Arrowsmith's proprietary synthetic engineering to modify phages, an approach that still must hold up against diverse clinical strains in human trials.
The signal: Founded only in February 2025, Arrowsmith has moved from incorporation to a Series A and an FDA Pre-IND meeting in barely a year, an unusually fast trajectory for an early-stage drug discovery startup. Backing from JIC Venture Growth Investments and DBJ Capital — both tied to Japan's state-linked investment apparatus — reflects how AMR has become a policy priority within the country's growth strategy, not just a venture bet.
Read more: PR Times
